Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
Fierce Pharma Asia—Astellas CEO’s 5-year plan; Takeda’s psoriasis win; RA’s China bridge program
Astellas CEO explained to Fierce the company's new five-year plan. A Takeda candidate beat Bristol Myers Squibb's Sotyktu in a head-to-head psoriasis trial. | Astellas CEO explained to Fierce the company's new five-year plan. A Takeda candidate beat Bristol Myers Squibb's Sotyktu in a head-to-head psoriasis trial. RA Capital is offering China capabilities to its portfolio companies through a one-year-old initiative. And more.
TL;DRAI
Astellas targets ¥200B cost cuts against patent cliff via R&D internalization; Takeda's TYK2 inhibitor beats Bristol Myers' Sotyktu with 35% psoriasis clearance. Patent cliff strategies and clinical wins drive pharma M&A cycles; WuXi AppTec blacklist exposes geopolitical risk in CDMO sourcing.
558 words~3 min read
